Updates in Oncogene-Driven NSCLC from Paris
Release date: 21-09-2022
Expiration date: 20-09-2023
Duration: 0.5 hours
The use of genomic profiling in tissue and liquid biopsy is expanding and provides a foundation for advancing precision medicine in lung cancer. New data are accumulating rapidly regarding the efficacy and safety of targeted therapy that has recently entered clinical practice, and the emerging strategies to target resistance mechanisms. In this Updates in Oncogene-Driven NSCLC, experts in the field discuss some of the new data on genomic profiling and targeted therapy in oncogene-driven NSCLC presented at the 2022 ESMO congress in Paris. Additionally, they will evaluate the potential impact of these findings on clinical practice and ongoing research.
David Planchard, MD, PhD | Moderator
David Planchard is a Thoracic Oncologist and Head of the Thoracic Pathology Committee at Gustave Roussy, Villejuif, France. He is also President of the International Centre for Thoracic Cancers (CICT), a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital, and the Paris Saint-Joseph Hospital.
During the last 20 years, Dr. Planchard’s primary research interests have focused on immunotherapy, genomic analysis and biomarkers, and targeted treatments of bronchial cancers. He has been involved in more than 150 phase I, II, and III clinical trials, with over 200 published articles. Dr. Planchard has been directly involved in trial design, having been co-director on trials in the field of thoracic tumors, with the aim to develop a long-term clinical research strategy based on molecular screening.
Dr. Planchard coordinated the latest European recommendations on the management of advanced-stage non-small cell lung cancer (ESMO guidelines) and has participated in many national and international conferences, including European Society for Medical Oncology (ESMO), European Lung Cancer Congress (ELCC), American Society of Clinical Oncology (ASCO), and World Conference on Lung Cancer (WCLC).
Egbert F. Smit, MD, PhD
Leiden University Medical Center
Leiden, The Netherlands
Egbert F. Smit is a Professor of Pulmonary Medicine in the Department of Pulmonary Diseases at Leiden University Medical Center, Leiden, the Netherlands. He graduated in 1988 from the University of Groningen, and earned his PhD with a thesis entitled Aspects of Chemotherapy for Lung Cancer. After obtaining his specialist degree in Pulmonary Medicine, Professor Smit held various positions in academia and in general hospitals.
Professor Smit conducts both preclinical and translational research involving all aspects of lung cancer. His research ranges from carcinogenesis to the treatment of metastatic lung cancer and has resulted in more than 450 peer-reviewed papers and 30 book chapters. He serves on the review board of major oncology journals, and he is a member of the European Society for Medical Oncology Faculty Group.
Daniel S.W. Tan, MBBS, MRCP, PhD, FAMS
National Cancer Centre Singapore
Daniel Tan is a Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore (NCCS), an Associate Professor at Duke-National Medical School, and a Senior Clinical-Scientist at the Genome Institute of Singapore. He is also Deputy Head of the Division of Clinical Trials and Epidemiological Sciences, and Director of the Experimental Cancer Therapeutics Unit (Phase I Unit) at NCCS. Dr Tan’s research interests are in thoracic and head and neck oncology, and cancer drug development. His work is focused on improving the understanding of determinants of response and resistance to targeted therapy and immunotherapy. He has published more than 100 peer-reviewed articles, many in high impact-factor journals. He has been the recipient of several national and international awards for his research, including the ASCO Merit Award twice, and in 2019, the IASLC Daniel C. Idhe Lectureship Award for Medical Oncology. Dr Tan serves as Associate Editor for the J Thoracic Oncol and is the conference co-chair for the World Conference in Lung Cancer (WCLC) in 2020, and the track chair for translational research at ESMO 2021.
This program is specifically designed for medical oncologists, pulmonologists, oncology fellows, and other healthcare professionals involved in the management of patients with lung cancer.
Upon completion of this educational activity, participants should be able to:
- Describe new data related to detection of resistance mechanism in EGFR mutant NSCLC and assess strategies to overcome resistance to third-generation EGFR tyrosine kinase inhibitors
- Evaluate new findings on targeted therapies for patients with advanced NSCLC with rare molecular alterations, KRAS G12C and early-stage EGFR-mutant NSCLC, and how they impact clinical practice
This activity is provided by ACE Oncology.
This educational activity is supported by an independent medical education grant from Merck KGaA, Darmstadt, Germany.
The Faculty of Pharmaceutical Medicine has approved this event for continuing professional development (CPD) and allocated it 0.5 CPD credits.
This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve the competence and performance of learners in order to improve patient care.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
David Planchard has served as an advisor or consultant for AstraZeneca, AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, Roche, and Samsung. He has also served as a speaker or a member of speakers bureau for AstraZeneca, AbbVie, Bristol Myers Squibb, Daiichi Sanyo, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, and Samsung. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Egbert F. Smit has served as an advisor or consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, DSI, Eli Lilly, Genentech, Merck Serono, MSD, Novartis, Pfizer, Roche, and Takeda. He has also received grants for clinical research from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis Oncology, Cullinan, Eli Lilly, Genentech, Merck, MSD, Novartis, PharmaMar, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Daniel Tan has served as an advisor or consultant for Novartis, Bayer, Boehringer Ingelheim, Celgene, AstraZeneca, Eli Lilly, and Loxo. He has received grants for clinical research from Novartis, AstraZeneca, Pfizer, and Bayer.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
To claim a credit certificate for completing this activity, follow these steps:
- Read the information provided on this page regarding the target audience, learning objectives, and disclosures. Read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test (minimum of 75%) and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
- Your CPD credit certificate will be issued and sent to you via e-mail.
We encourage you to complete the evaluation to provide feedback for future educational programming.